- Report
- August 2022
Global
From €1038EUR$1,090USD£887GBP
- Report
- November 2022
- 164 Pages
Global
From €3328EUR$3,495USD£2,844GBP
- Clinical Trials
- January 2020
- 658 Pages
Global
From €2380EUR$2,500USD£2,035GBP
- Drug Pipelines
- June 2020
- 4664 Pages
Global
From €2380EUR$2,500USD£2,035GBP
- Newsletter
- March 2024
Global
From €1010EUR$1,136USD£894GBP
- Report
- February 2024
- 101 Pages
Global
From €3500EUR$3,938USD£3,096GBP
- Report
- May 2022
- 99 Pages
Global
From €3500EUR$3,938USD£3,096GBP
- Report
- December 2022
- 2271 Pages
Global
From €2380EUR$2,500USD£2,035GBP
- Report
- May 2022
- 148 Pages
Global
From €2380EUR$2,500USD£2,035GBP
- Report
- October 2022
- 262 Pages
Global
From €5455EUR$5,730USD£4,663GBP
- Report
- April 2023
- 160 Pages
Global
From €5712EUR$5,999USD£4,882GBP
The Non Small Cell Lung Cancer Drug market is a subset of the larger Lung Cancer Drug market. Non Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases. NSCLC is typically treated with chemotherapy, radiation, and targeted therapies. Targeted therapies are drugs that target specific molecules involved in the growth and spread of cancer cells. These drugs are designed to block the growth and spread of cancer cells while limiting damage to healthy cells.
The Non Small Cell Lung Cancer Drug market is highly competitive, with a number of companies offering various treatments. Companies such as AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, and Pfizer are some of the major players in the market. Other companies such as Amgen, Boehringer Ingelheim, and Novartis are also active in the market. Show Less Read more